Ferreira Juan Camilo Arjona Sells 4,632 Shares of Myovant Sciences Ltd. (NYSE:MYOV) Stock

Myovant Sciences Ltd. (NYSE:MYOV – Get Rating) insider Ferreira Juan Camilo Arjona sold 4,632 shares of the firm’s stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $10.45, for a total value of $48,404.40. Following the completion of the sale, the insider now directly owns 260,129 shares of the company’s stock, valued at approximately $2,718,348.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ferreira Juan Camilo Arjona also recently made the following trade(s):

• On Tuesday, April 5th, Ferreira Juan Camilo Arjona sold 1,922 shares of Myovant Sciences stock. The stock was sold at an average price of $13.78, for a total value of $26,485.16.

Shares of NYSE:MYOV opened at $9.38 on Friday. Myovant Sciences Ltd. has a 12-month low of $9.18 and a 12-month high of $27.43. The company has a market capitalization of $880.83 million, a PE ratio of -3.80 and a beta of 2.74. The business has a 50 day moving average of $12.73 and a two-hundred day moving average of $15.72.

Myovant Sciences (NYSE:MYOV – Get Rating) last posted its quarterly earnings data on Wednesday, January 26th. The company reported ($0.68) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.59) by ($0.09). The firm had revenue of $54.44 million during the quarter, compared to analyst estimates of $54.50 million. During the same period in the previous year, the business earned ($0.82) EPS. On average, equities research analysts anticipate that Myovant Sciences Ltd. will post -2.18 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Cubist Systematic Strategies LLC increased its position in shares of Myovant Sciences by 268.9% in the third quarter. Cubist Systematic Strategies LLC now owns 45,553 shares of the company’s stock valued at $1,022,000 after buying an additional 33,204 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Myovant Sciences in the third quarter valued at approximately $369,000. Russell Investments Group Ltd. increased its position in shares of Myovant Sciences by 100.6% in the third quarter. Russell Investments Group Ltd. now owns 10,814 shares of the company’s stock valued at $241,000 after buying an additional 5,423 shares in the last quarter. Two Sigma Investments LP purchased a new stake in shares of Myovant Sciences in the third quarter valued at approximately $1,013,000. Finally, Jump Financial LLC purchased a new stake in shares of Myovant Sciences during the third quarter worth approximately $2,093,000. Institutional investors and hedge funds own 33.78% of the company’s stock.

MYOV has been the subject of a number of research reports. SVB Leerink decreased their target price on Myovant Sciences from $19.00 to $12.00 and set a “market perform” rating for the company in a report on Wednesday, April 13th. Robert W. Baird decreased their target price on Myovant Sciences from $30.00 to $20.00 in a report on Wednesday, April 13th. StockNews.com initiated coverage on Myovant Sciences in a report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Zacks Investment Research downgraded Myovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, March 23rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Myovant Sciences presently has a consensus rating of “Hold” and an average target price of $22.00.

About Myovant Sciences (Get Rating)

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Further Reading